In prostatic cancer research three-dimensional conformal radiation therapy (3-D CRT), brachytherapy and new therapeutic modalities have been applied. Treatment planning and delivery of radiation therapy have substantially evolved in the past 20 years. The treatment of localized carcinoma of the prostate with 3-D CRT is described, preliminary clinical results are presented and compared with those with standard radiation therapy (SRT). The benefit of 3-D CRT hypothetically could be linked to improved local tumor control because of a better coverage of the target volume with a specific dose of irradiation, less acute and late toxicity, possibility of carrying out dose-escalation studies. Intensity modulated radiation therapy (IMRT) may be particularly useful in some cases. Further efforts are necessary with collaboration of urologists and radiation oncologists to continue to explore approaches to optimally select and manage patients with localized prostate cancer. A reliable assessment of the impact of 3-D CRT and IMRT on outcome should come from prospective randomized long-term studies. As for brachytherapy, standardized protocols should be developed to objectively evaluate brachytherapy in localized prostatic cancer. Recently a great deal of interest has been focused on new therapeutic modalities with chemotherapeutic agents, a new agent named prostate specific enhancer, a regulatory element of the PSA gene is being tested. Laboratory and animal studies of the viral construct have been reported. A phase I human clinical trial is being initiated in the U.S.A. in patients with postirradiation hormone refractory prostate cancer.
|Number of pages||13|
|State||Published - 2000|